Shcell

4 Chinese Immunotherapy Companies to Keeps Tabs on in 2019

Four Chinese pharmaceuticals are developing promising cancer immunotherapy drugs. Along with the advantageous policies and unmet needs within China's healthcare ecosystem, they will presumably shine for patients and investors in 2019.

EqualOcean and Skepsos Sign Strategic Cooperation Memorandum of Understanding

On May 20, 2025, Beijing EO Technology Co.,Ltd and the Greater Paris Health Industry Park (Skepsos) officially signed a Memorandum of Understanding on Strategic Cooperation in Beijing.

Biotech in China: Oasis in the Desert?

Following AstraZeneca's USD 1 billion-large capital injection plans with China's state-backed CICC, and I-Mab Biopharma's long-anticipated IPO, all eyes are back on China's lucrative Biotech scene. EqualOcean sums up the story.

Shanghai Cell Theraphy Group Completes CNY 650 Million Series C2

Shanghai Cell Therapy Group has completed CNY 650 million -the equivalent of approximately USD 95 million,- in Series C2 financing at an undisclosed time.

Shanghai Cell Therapy Creates A Record in Series C Funding

Shanghai Cell completed series C funding iao USD 134.29 million led by CPIC, Haier Capital, and China Industrial Asset Management.